Form 4: Applied Therapeutics Executive Receives Stock and Options as Interim CEO

Leslie D. Funtleyder, interim CEO of Applied Therapeutics, received 150,000 shares of restricted stock units and 150,000 stock options as part of his compensation.

Summary

• Leslie D. Funtleyder, the interim CEO of Applied Therapeutics, received 150,000 restricted stock units (RSUs) and 150,000 stock options on December 19, 2024.
• The RSUs and options were granted under the company's 2019 Equity Incentive Plan as compensation for his role as interim CEO.
• The RSUs and options vest in equal monthly installments over 12 months, contingent on his continued service.
• All unvested RSUs and options will vest immediately upon FDA approval of the company's Sorbitol Dehydrogenase drug application or a change in control of the company.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally positive for aligning management with shareholder interests. The vesting terms are also positive, incentivizing performance and continued service.

Positives

• The grant of RSUs and options aligns the interim CEO's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and performance.
• The accelerated vesting upon FDA approval or change in control provides a strong incentive for successful outcomes.

Risks

• The vesting of the RSUs and options is contingent on continued service, which could be a risk if the interim CEO leaves before the vesting period is complete.
• The accelerated vesting is dependent on FDA approval of the Sorbitol Dehydrogenase drug or a change in control, which are not guaranteed.

Future Outlook

The vesting of the RSUs and options is tied to the continued service of the interim CEO and the potential FDA approval of the Sorbitol Dehydrogenase drug or a change in control.

Management Comments

• Leslie D. Funtleyder is serving as the interim Chief Executive Officer and Chief Financial Officer.

Industry Context

This type of equity compensation is common for executives, especially interim leaders, in the biotechnology industry to align their interests with the company's success and incentivize performance.

Comparison to Industry Standards

• Equity grants are a standard practice for executive compensation in the biotech industry, often including a mix of stock options and restricted stock units.
• Vesting schedules tied to service and milestones like FDA approvals are also common.
• The specific terms of the grant, such as the vesting period and the triggers for accelerated vesting, are typical for companies in a similar stage of development as Applied Therapeutics.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use similar equity compensation structures for their executives.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of alignment between management and shareholder interests.
• Employees may see the compensation structure as a positive incentive for the interim CEO to drive company success.

Next Steps

• The interim CEO will continue to provide services to the company.
• The company will continue to pursue FDA approval for its Sorbitol Dehydrogenase drug application.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, interim CEO, FDA approval, vesting, equity incentive plan, change in control, Sorbitol Dehydrogenase, APLT